These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30267009)

  • 1. Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes.
    Rydén J; Edgren G; Karimi M; Walldin G; Tobiasson M; Wikman A; Hellström-Lindberg E; Höglund P
    Leukemia; 2019 Feb; 33(2):522-527. PubMed ID: 30267009
    [No Abstract]   [Full Text] [Related]  

  • 2. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression.
    DiNardo CD; Jabbour E; Ravandi F; Takahashi K; Daver N; Routbort M; Patel KP; Brandt M; Pierce S; Kantarjian H; Garcia-Manero G
    Leukemia; 2016 Apr; 30(4):980-4. PubMed ID: 26228814
    [No Abstract]   [Full Text] [Related]  

  • 3. Initial transfusion intensity predicts survival in myelodysplastic syndrome.
    Chan LS; Shapiro R; Buckstein R; Lin Y; Callum J; Chodirker L; Lee CD; Prica A; Lam A; Mamedov A; Wells RA
    Leuk Lymphoma; 2014 Oct; 55(10):2296-300. PubMed ID: 24397595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
    Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
    Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic mutations in persons with isolated neutropenia myelodysplastic syndrome.
    Shi Z; Qin T; Xu Z; Li B; Huang H; Zhang H; Fang L; Pan L; Hu N; Qu S; Huang G; Gale RP; Xiao Z
    Leuk Lymphoma; 2019 Nov; 60(11):2835-2837. PubMed ID: 31056995
    [No Abstract]   [Full Text] [Related]  

  • 6. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.
    de Swart L; Reiniers C; Bagguley T; van Marrewijk C; Bowen D; Hellström-Lindberg E; Tatic A; Symeonidis A; Huls G; Cermak J; van de Loosdrecht AA; Garelius H; Culligan D; Macheta M; Spanoudakis M; Panagiotidis P; Krejci M; Blijlevens N; Langemeijer S; Droste J; Swinkels DW; Smith A; de Witte T;
    Haematologica; 2018 Jan; 103(1):69-79. PubMed ID: 29122992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-Iron: a phase 2 trial of the activity and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent myelodysplastic syndromes.
    Killick S; Jackson A; Coulthard HC; Yap C; Das-Gupta E; Pennell DJ; Porter J; Bowen D; Culligan D
    Br J Haematol; 2020 Jun; 189(6):e237-e240. PubMed ID: 32342485
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of cardiovascular events and all-cause of death in patients with transfusion-dependent myelodysplastic syndrome.
    Alonso-Fernandez-Gatta M; Martin-Garcia A; Martin-Garcia AC; Lopez-Cadenas F; Diaz-Pelaez E; Jimenez-Solas T; Gonzalez-Martinez T; Sanchez-Pablo C; Diez-Campelo M; Sanchez PL
    Br J Haematol; 2021 Nov; 195(4):536-541. PubMed ID: 34180544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care.
    Bell JA; Galaznik A; Blazer M; Farrelly E; Ogbonnaya A; Raju A; Eaddy M; Fram RJ; Faller DV
    Leuk Lymphoma; 2019 Jan; 60(1):49-59. PubMed ID: 29932781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors predicting overall survival in Moroccan patients with myelodysplastic syndrome.
    Jennane S; Amelal S; El Mehdi M; Ahid S; Messaoudi N; Doghmi K; Mikdame M
    Tunis Med; 2016; 94(8-9):541-545. PubMed ID: 28603827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Male predominance in AML is associated with specific preleukemic mutations.
    De-Morgan A; Meggendorfer M; Haferlach C; Shlush L
    Leukemia; 2021 Mar; 35(3):867-870. PubMed ID: 32576964
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.
    Hoeks M; Bagguley T; van Marrewijk C; Smith A; Bowen D; Culligan D; Kolade S; Symeonidis A; Garelius H; Spanoudakis M; Langemeijer S; Roelofs R; Wiegerinck E; Tatic A; Killick S; Panagiotidis P; Stanca O; Hellström-Lindberg E; Cermak J; van der Klauw M; Wouters H; van Kraaij M; Blijlevens N; Swinkels DW; de Witte T;
    Leukemia; 2021 Jun; 35(6):1745-1750. PubMed ID: 32948844
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome.
    Lucijanić M; Pejša V; Mitrović Z; Štoos-Veić T; Livun A; Jakšić O; Vasilj T; Piršić M; Hariš V; Prka Ž; Kušec R
    Hematology; 2016 Apr; 21(3):170-4. PubMed ID: 27077775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis and therapy of myelodysplastic syndromes.
    Estey EH
    Cancer Treat Res; 1993; 64():233-67. PubMed ID: 8095794
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV portends a poor prognosis in myelodysplastic syndromes.
    Kaner JD; Thibaud S; Jasra S; Wang Y; Janakiram M; Sharma A; Sridharan A; Elias H; Polineni R; Assal A; Weiss L; Braunschweig I; Steidl U; Pradhan K; Shastri A; Chaitowitz M; Zingman B; Will B; Mantzaris I; Verma A
    Leuk Lymphoma; 2019 Dec; 60(14):3529-3535. PubMed ID: 31282240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the path ahead in myelodysplastic syndrome.
    List A
    Am J Hematol; 2010 Mar; 85(3):157-8. PubMed ID: 20143403
    [No Abstract]   [Full Text] [Related]  

  • 18. [9th Antonio Raichs memorial lecture. Myelodysplastic syndromes].
    Giralt M
    Sangre (Barc); 1997 Feb; 42(1):63-71. PubMed ID: 9229805
    [No Abstract]   [Full Text] [Related]  

  • 19. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.
    Thol F; Weissinger EM; Krauter J; Wagner K; Damm F; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Haematologica; 2010 Oct; 95(10):1668-74. PubMed ID: 20494930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies.
    Wan Z; Han B
    Aging (Albany NY); 2021 Mar; 13(8):11120-11134. PubMed ID: 33818418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.